Business Description
Diamyd Medical AB
ISIN : SE0005162880
Share Class Description:
FRA:DMN: Class BCompare
Compare
Traded in other countries / regions
DMYD B.SwedenDMN.GermanyDYMDF.USA IPO Date
2018-08-28Description
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.32 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 6.6 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -37 | |||||
| 3-Year EPS without NRI Growth Rate | -8.2 | |||||
| 3-Year FCF Growth Rate | 3 | |||||
| 3-Year Book Growth Rate | -17.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -4.98 | |||||
| Future 3-5Y Total Revenue Growth Rate | 449.23 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.42 | |||||
| 9-Day RSI | 62.62 | |||||
| 14-Day RSI | 56.77 | |||||
| 6-1 Month Momentum % | 12.93 | |||||
| 12-1 Month Momentum % | 89.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.98 | |||||
| Quick Ratio | 3.98 | |||||
| Cash Ratio | 3.31 | |||||
| Days Sales Outstanding | 112.84 | |||||
| Days Payable | 846.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.8 | |||||
| Shareholder Yield % | -11.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -2732.06 | |||||
| Operating Margin % | -112422.9 | |||||
| Net Margin % | -115916.03 | |||||
| FCF Margin % | -108836.36 | |||||
| ROE % | -84.13 | |||||
| ROA % | -65.39 | |||||
| ROIC % | -193.69 | |||||
| ROC (Joel Greenblatt) % | -283.05 | |||||
| ROCE % | -73.59 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12700 | |||||
| PB Ratio | 8.68 | |||||
| Price-to-Tangible-Book | 10.29 | |||||
| EV-to-EBIT | -9.41 | |||||
| EV-to-Forward-EBIT | -7.62 | |||||
| EV-to-EBITDA | -10.11 | |||||
| EV-to-Forward-EBITDA | -7.88 | |||||
| EV-to-Revenue | 10883.89 | |||||
| EV-to-Forward-Revenue | 386.08 | |||||
| EV-to-FCF | -8.89 | |||||
| Price-to-Median-PS-Value | 18.87 | |||||
| Price-to-Net-Current-Asset-Value | 16.17 | |||||
| Price-to-Net-Cash | 22.64 | |||||
| Earnings Yield (Greenblatt) % | -10.65 | |||||
| FCF Yield % | -8.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Diamyd Medical AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.011 | ||
| EPS (TTM) (€) | -0.139 | ||
| Beta | 1.98 | ||
| Volatility % | 101.06 | ||
| 14-Day RSI | 56.77 | ||
| 14-Day ATR (€) | 0.039364 | ||
| 20-Day SMA (€) | 1.044 | ||
| 12-1 Month Momentum % | 89.91 | ||
| 52-Week Range (€) | 0.55 - 1.784 | ||
| Shares Outstanding (Mil) | 104.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Diamyd Medical AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Diamyd Medical AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Diamyd Medical AB Frequently Asked Questions
What is Diamyd Medical AB(FRA:DMN)'s stock price today?
The current price of FRA:DMN is €1.13. The 52 week high of FRA:DMN is €1.78 and 52 week low is €0.55.
When is next earnings date of Diamyd Medical AB(FRA:DMN)?
The next earnings date of Diamyd Medical AB(FRA:DMN) is 2025-01-29.
Does Diamyd Medical AB(FRA:DMN) pay dividends? If so, how much?
Diamyd Medical AB(FRA:DMN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers